Abstract

NATURAL PHYTOCHEMICALS AND FLAVONOIDS IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS AND ITS COMPLICATIONS: A COMPREHENSIVE LITERATURE REVIEW

Dr. Praveen Kumar N*, Dr. Mariyam Begum, Mohd. Sameer Khan, Mizba Tabassum, Midde Lavanya

ABSTRACT

Background: Type 2 diabetes mellitus (T2DM) remains one of the most prevalent non-communicable metabolic disorders worldwide, and its associated micro- and macrovascular complications — nephropathy, retinopathy, neuropathy, and cardiovascular disease — substantially increase morbidity, mortality, and healthcare burden. Conventional pharmacotherapy, while effective, is frequently limited by adverse effects, secondary treatment failure, and cost, motivating sustained interest in plant-derived phytochemicals, particularly flavonoids, as adjunctive or complementary therapeutic agents. Objective: This comprehensive literature review synthesizes and critically appraises contemporary evidence (2021–2026) on the antidiabetic and complication-protective properties of natural flavonoids and related phytochemicals (including berberine, curcumin, and resveratrol) in the context of T2DM management. Methods: A structured, PRISMA-informed search of PubMed/MEDLINE, PubMed Central, ScienceDirect, and Google Scholar was conducted. Following title/abstract screening and full-text eligibility assessment, 58 sources — comprising randomized controlled trials, systematic reviews and meta-analyses, prospective cohort studies, nanoformulation/drug-delivery reviews, and mechanistic/narrative reviews — were retained for qualitative synthesis. Results: Flavonoid subclasses, notably flavonols (quercetin, kaempferol), flavanones (naringenin, hesperetin), flavan-3-ols (catechins), anthocyanins, and isoflavones, together with non-flavonoid phytochemicals such as berberine, curcumin, and resveratrol, demonstrated consistent glucose-lowering and insulin-sensitizing effects across preclinical and clinical studies. Mechanistically, these compounds act through α-glucosidase/α-amylase inhibition, activation of insulin-signaling pathways (PI3K/Akt, AMPK), pancreatic β-cell protection, modulation of NF-κB/Nrf2-mediated inflammatory and oxidative stress pathways, and remodeling of gut microbiota composition. Clinical trials and meta-analyses of berberine, curcumin, citrus flavonoids, and resveratrol reported statistically significant reductions in fasting blood glucose and glycated hemoglobin (HbA1c), although effect magnitudes varied with dose, formulation, and trial duration. Prospective cohort studies consistently associated higher habitual flavonoid intake with reduced T2DM incidence (hazard/incidence rate ratios ranging from approximately 0.54 to 0.85 for highest versus lowest intake categories). Emerging evidence additionally supports a protective role for flavonoids and anthocyanins against diabetic nephropathy, retinopathy, neuropathy, and cardiovascular complications, although robust long-term human trial data for these complication-specific outcomes remain comparatively limited. Conclusion: Natural flavonoids and related phytochemicals represent a biologically plausible and increasingly evidence-supported adjunct in the multimodal management of T2DM and its complications. However, heterogeneity in study design, dosing, formulation, and outcome reporting, combined with persistent bioavailability limitations, currently precludes definitive clinical recommendations. Well-powered, standardized randomized controlled trials and continued development of bioavailability-enhancing nanoformulations are warranted to translate this mechanistic and epidemiological promise into validated clinical practice.

Keywords: Type 2 diabetes mellitus; Flavonoids; Phytochemicals; Quercetin; Kaempferol; Berberine; Curcumin; Resveratrol; Insulin resistance; Diabetic complications; Diabetic nephropathy; Diabetic retinopathy; Diabetic neuropathy; Oxidative stress; Gut microbiota; N